The global demand for Secukinumab Market is presumed to reach the market size of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period 2022 - 2028.
Secukinumab, commonly identified as Cosentyx, is a prescription drug used for treating moderate-to-severe plaque psoriasis, a kind of skin disease, in adults. It is used for treating psoriatic arthritis, which causes pain and swelling in joints. This medication also treats ankylosing spondylitis, which causes pain, swelling and damage to joints in the spine. In psoriatic arthritis and ankylosing spondylitis, the natural protein IL-17A causes pain and inflammation of the joints and Secukinumab blocks this inflammatory protein. It is an immunosuppressant and belongs to the monoclonal antibody family. It is administered subcutaneously as an injection. Some of its common side effects are sore throat, diarrhoea, sinus infection, tonsillitis and runny nose.
The Secukinumab market is predicted to register significant growth during the forecast period. The key factor driving the market is increasing incidence of ankylosing spondylitis, psoriatic arthritis and skin disorders like plaque psoriasis. Increasing expenditure on healthcare is another major factor driving the market. Companies focusing on clinical trials for treatment of psoriasis will propel market growth. The fact that patients are demanding faster recovery from palmoplantar and nail psoriasis with less side effects will have a positive impact on the market. In addition, growing awareness about psoriasis and initiatives being taken by the government will magnify its demand. However, introduction of JAK inhibitors, novel biologics and biosimilars may restrict the growth of Secukinumab market during the evaluation period.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of secukinumab. The growth and trends of secukinumab industry provide a holistic approach to this study.
This section of the secukinumab market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Product Type`
By Drug Class
- Sensoready Pen
- Prefilled Syringe
- Powder For Solution
- Interleukin Inhibitors
By Dosage Form
By Distribution Channel
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Plaque Psoriasis
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
This section covers the regional outlook, which accentuates current and future demand for the Secukinumab market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Secukinumab Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the secukinumab market include Novartis AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.